% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sannemann:270674,
      author       = {Sannemann, Lena and Bartels, Claudia and Brosseron,
                      Frederic and Buerger, Katharina and Fliessbach, Klaus and
                      Freiesleben, Silka Dawn and Frommann, Ingo and Glanz, Wenzel
                      and Heneka, Michael and Janowitz, Daniel and Kilimann, Ingo
                      and Kleineidam, Luca and Lammerding, Dominik and Laske,
                      Christoph and Munk, Matthias H J and Perneczky, Robert and
                      Peters, Oliver and Priller, Josef and Rauchmann, Boris
                      Stephan and Rostamzadeh, Ayda and Roy-Kluth, Nina and
                      Schild, Ann-Katrin and Schneider, Anja and Schneider,
                      Luisa-Sophie and Spottke, Annika and Spruth, Eike Jakob and
                      Teipel, Stefan and Wagner, Michael and Wiltfang, Jens and
                      Wolfsgruber, Steffen and Duezel, Emrah and Jessen, Frank},
      collaboration = {Group, DELCODE Study},
      title        = {{S}ymptomatic {C}lusters {R}elated to {A}myloid
                      {P}ositivity in {C}ognitively {U}nimpaired {I}ndividuals.},
      journal      = {Journal of Alzheimer's disease},
      volume       = {100},
      number       = {1},
      issn         = {1387-2877},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {DZNE-2024-00846},
      pages        = {193 - 205},
      year         = {2024},
      abstract     = {The NIA-AA Research Framework on Alzheimer's disease (AD)
                      proposes a transitional stage (stage 2) characterized by
                      subtle cognitive decline, subjective cognitive decline (SCD)
                      and mild neurobehavioral symptoms (NPS).To identify
                      participant clusters based on stage 2 features and assess
                      their association with amyloid positivity in cognitively
                      unimpaired individuals.We included baseline data of N = 338
                      cognitively unimpaired participants from the DELCODE cohort
                      with data on cerebrospinal fluid biomarkers for AD.
                      Classification into the AD continuum (i.e., amyloid
                      positivity, A+) was based on Aβ42/40 status.
                      Neuropsychological test data were used to assess subtle
                      objective cognitive dysfunction (OBJ), the subjective
                      cognitive decline interview (SCD-I) was used to detect SCD,
                      and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was
                      used to assess NPS. A two-step cluster analysis was carried
                      out and differences in AD biomarkers between clusters were
                      analyzed.We identified three distinct participant clusters
                      based on presented symptoms. The highest rate of A+
                      participants $(47.6\%)$ was found in a cluster characterized
                      by both OBJ and SCD. A cluster of participants that
                      presented with SCD and NPS $(A+:26.6\%)$ and a cluster of
                      participants with overall few symptoms $(A+:19.7\%)$ showed
                      amyloid positivity in a range that was not higher than the
                      expected A+ rate for the age group. Across the full sample,
                      participants with a combination of SCD and OBJ in the memory
                      domain showed a lower Aβ42/ptau181 ratio compared to those
                      with neither SCD nor OBJ.The cluster characterized by
                      participants with OBJ and concomitant SCD was enriched for
                      amyloid pathology.},
      keywords     = {Humans / Male / Female / Amyloid beta-Peptides:
                      cerebrospinal fluid / Amyloid beta-Peptides: metabolism /
                      Aged / Cognitive Dysfunction: cerebrospinal fluid /
                      Cognitive Dysfunction: psychology / Cognitive Dysfunction:
                      diagnosis / Biomarkers: cerebrospinal fluid / Peptide
                      Fragments: cerebrospinal fluid / Neuropsychological Tests /
                      Alzheimer Disease: cerebrospinal fluid / Alzheimer Disease:
                      psychology / Alzheimer Disease: diagnosis / Middle Aged /
                      Cohort Studies / Aged, 80 and over / Cluster Analysis /
                      Alzheimer’s disease (Other) / Alzheimer’s disease
                      (Other) / Alzheimer’s disease continuum (Other) / NIA-AA
                      stage 2 (Other) / amyloid (Other) / cerebrospinal fluid
                      biomarkers (Other) / neuropsychiatric symptoms (Other) /
                      preclinical Alzheimer’s disease (Other) / subjective
                      cognitive decline (Other) / Amyloid beta-Peptides (NLM
                      Chemicals) / Biomarkers (NLM Chemicals) / Peptide Fragments
                      (NLM Chemicals) / amyloid beta-protein (1-42) (NLM
                      Chemicals) / Alzheimer’s disease continuum (Other) /
                      preclinical Alzheimer’s disease (Other)},
      cin          = {AG Jessen / AG Heneka / Clinical Research (Munich) /
                      Patient Studies Bonn ; Patient Studies (Bonn) / AG Peters /
                      AG Wagner / AG Düzel / AG Teipel / AG Gasser / AG Dichgans
                      / AG Priller / AG Spottke / AG Wiltfang},
      ddc          = {610},
      cid          = {I:(DE-2719)1011102 / I:(DE-2719)1011303 /
                      I:(DE-2719)1111015 / I:(DE-2719)1011101 / I:(DE-2719)5000000
                      / I:(DE-2719)1011201 / I:(DE-2719)5000006 /
                      I:(DE-2719)1510100 / I:(DE-2719)1210000 / I:(DE-2719)5000022
                      / I:(DE-2719)5000007 / I:(DE-2719)1011103 /
                      I:(DE-2719)1410006},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      experiment   = {EXP:(DE-2719)DELCODE-20140101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38848176},
      doi          = {10.3233/JAD-231335},
      url          = {https://pub.dzne.de/record/270674},
}